Keeping cleanrooms clean takes more than soap and water. A lot more.
Disinfectant efficacy must be established before a new disinfectant can be put on the market. Additionally, manufacturers must validate disinfectant regimens for cleanroom and other controlled areas. Many different standards apply, including AOAC Chapter 6 tests, ASTM E 2315, USP General Chapter 1072 and ASTM E 26140.
It’s a complicated — but critical — topic for drug, device, biologics and supplement makers, and compounders too. They’ve seen a rise in the number and species of bacterial endospores and mold spores — and a rise in warning letters and Forms 483 too.
Now FDAnews is calling on Jim Polarine Jr., a recognized authority on disinfectant testing and validation, to clear the air.
Mark your calendar for Thursday, June 29, when Mr. Polarine lays out the problems facing manufacturers plus state-of-the-art solutions. You’ll discover:
Proven ways to limit cleanroom contamination from incoming items
Proper cleanroom design and condition
Best products to control bacterial and mold spores
Current sporicide and disinfectant regulations in the U.S. and the E.U.
Proven approaches to coupon testing and determining spore contamination sources
And much more!
You’ll address control of resistant species such as Bacillus cereus, and walk through case studies on testing intricacies including porosity of surfaces, surface sterilization, and pooling on surfaces.
Don’t risk patient safety, lawsuits and liability, warning letters or Forms 483. Learn how to keep cleanrooms really clean. Sign up today.